In early May 2015, the immunotherapy technology developed by Prof. Chang Myung-hee of Tsinghua University Medical Center announced the results of Phase 1 clinical outcome. More than 70% of patients treated for more than one year reported a clear effect.

Immune cell therapy technology is the fourth treatment following surgery and radiotherapy chemotherapy. It activates the immune system to prevent tumor recurrence and metastasis, so that the patient's chemotherapy reduces the immune system and reduces the quality of life. We released the results. Cell-mediated immunotherapy has become a new trend in cancer treatment with internationally advanced medical technology. According to the Japanese Ministry of Health, Labor and Welfare in 2006, PROVENGE of prostate cancer treatment of US DENDREON company was introduced in 2010, Canadian scholars have been selected for DC cell research. 

There is CAR-T immunotherapy technology which has been studied with international interest. The principle is to find and kill cancer cells through modified T cells. Small clinical data show that patients with B-cell lymphoma that are not effective for other therapies have a complete remission rate of 60% with CAR-T therapy. However, it also has side effects that can lead to the deficiency of protein immune cells by attacking normal B cells with the same tumor antigen. We are exploring ways to overcome these side effects of CAR-T therapy. Unlike CAR-T therapy, Prof. Chang Myung-Ki's team is working on NKT immunotherapy, which is part of immunotherapy. NKT cells have the advantage of protecting normal cells while attacking tumor cells. In fact, the biggest difference is that CAR-T therapy attacks and finds the correct target, and NKT cell therapy can be performed with effective control over many tumors. 

According to current oncology and immunology theories, it is not easy to find an accurate target for many tumors, but it is true that the immune system can basically distinguish normal cells from cancer cells. NKT cells are an important component of the immune system in identifying tumors. So, the team announced that it is expected that the combination of immunotherapy and general treatment will turn into a chronic disease, not a death caused by a malignant tumor. In 2010, Prof. Jang Myung-hui's team received national funding for NKT immunotherapy in recognition of the originality and excellence of technology. Since 2010, more than 60 patients with end-stage tumors have been supported, and patients who have been recruited have obtained safety and advanced clinical results. In the tumor immunotherapy market, many studies have been published through many investments. According to an American research report, it has a market value of over $ 25 billion and is showing a positive response to the treatment technology to be developed in the future. Immunotherapy is different from the pharmaceutical company model, which is mass-produced by technology rather than medicine, but it is worth more than that through special technology. 

He asked questions and talked about his research and future treatment techniques. We talked about the opinion that immunotherapy can not be an answer to tumor treatment, and asked about the idea of ​​CAR-T treatment being studied internationally. Dr. Jang said, "Immunotherapy, which is a defense against immune system, is the most promising therapeutic technique to control and maintain tumor growth. It is true that CAR-T treatment for B cell lymphoma is very effective but also has side effects. At the same time, the response to normal cells may cause neurotoxin. However, theoretically, if these modified T cells persist or are out of control in the body, they may cause immune deficiency due to the absence of B cells in the body. Thus, there are many factors that need to be supplemented to effectively control the time and amount of survival of the body in CAR-T cells and their deficiencies. Therefore, sophistication in tumor therapy is such a difficult technology. I have been searching for the target mainly on the specificity of the tumor internationally. But it is the reality that it is difficult to find as long as that period. The complexity of the immune system and the process of finding a response to tumors is complex, and a lot of research is needed in the future to find one precise target to be joined. So immunotherapy is another way of doing things with these therapeutic theories. " 

In immune cell therapy, the following questions were answered as to whether an accurate target is needed: "The immune system is complex. The tumor is like a contradiction in human society. In the process of tumor formation, there is a problem with the magnetic gene and a loophole in the immune system. Immune response refers to destroying an invading enemy. This is a variation of each. The important thing is to find out the loopholes of the immune system and to realize the control of the tumor, not the extinction. In my experience, the control of the immune system against tumors is currently hard to explain in theory. But with innovative technology and drugs, we have reached a technology that can control tumors over a period of time. We need to consider several things including the safety of the technique and the patient's pain reduction. Immunotherapy is also one of those techniques. There are many medicinal examples of this. Penicillin, for example, has been discovered and applied and applied clinically for many years, but its mechanism of action has been reported more accurately after 30 years. In the history of immunology there are many applications for vaccine applications. " 

I gave the following opinion about the question about NKT treatment. "The name NKT originated 20 years ago, and research in this area has been sluggish. These cells occupy only 1% of the immune system in very small amounts. And there are many kinds. NKT cells are able to grow rapidly in our basic research and applications by securing the technology to multiply in vitro. Tsinghua University has treated 13 patients over a year of clinical treatment with the People's Liberation Army Hospital, 10 of which have improved radiographically and all other figures have been effective. Therefore, we are trying to increase the number of patients to obtain more treatment information data. It is anticipated that more patients will benefit from the evaluation of treatment effectiveness. This treatment is expected to be commercialized soon, and the therapeutic effect will soon be revealed. "